Literature DB >> 15570641

Primary antiphospholipid syndrome: a 5-year transesophageal echocardiographic followup study.

Nilda Espinola Zavaleta1, Rosa María Montes, María Elena Soto, Nidia Avila Vanzzini, Mary-Carmen Amigo.   

Abstract

OBJECTIVE: To study valvular abnormalities in patients with primary antiphospholipid syndrome (APS) assessed by transesophageal echocardiography (TEE).
METHODS: This was a 5-year followup study. Between 1995 and 1997, 29 consecutive patients with primary APS were studied by TEE. Twenty-four patients were evaluated in our institution and 5 were referred from elsewhere. Four patients had died, 12 patients had the 5-year followup TEE, and 8 failed to report for the study.
RESULTS: In the first TEE, valve lesions were found in 17 patients (70.8%), myocardial infarction in 5 cases (29.4%), pulmonary hypertension in 4 (23.5%), and a calcified thrombus in the right atrium in one patient. Five-year followup TEE was performed in 12 patients. Valve lesions were unchanged in 3 cases, and in one of them a new apical akinesis of the left ventricle appeared. New valve lesions were detected in 3 patients. In 6 patients, the valve lesions had progressed and in 2, abnormalities of ventricular wall motion had appeared.
CONCLUSION: In this highly selected population of patients with primary APS, the predominant cardiac lesion was a noninfective valve lesion. Oral anticoagulant treatment and aspirin proved ineffective in terms of valvular lesion regression. Altogether, myocardial infarction occurred in 9 (37.5%) patients. All had coronary angiography and coronary arteries were normal in 6.

Entities:  

Mesh:

Year:  2004        PMID: 15570641

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  13 in total

Review 1.  Difficult clinical situations in the antiphospholipid syndrome.

Authors:  Renata Ferreira Rosa; Michelle Remião Ugolini-Lopes; Audrey Krüse Zeinad-Valim; Elbio D'Amico; Danieli Andrade
Journal:  Curr Rheumatol Rep       Date:  2015-04       Impact factor: 4.592

Review 2.  The clinical significance of antiphospholipid antibodies in systemic lupus erythematosus.

Authors:  Ozan Ünlü; Stephane Zuily; Doruk Erkan
Journal:  Eur J Rheumatol       Date:  2015-12-29

3.  Close association between valvar heart disease and central nervous system manifestations in the antiphospholipid syndrome.

Authors:  I Krause; S Lev; A Fraser; M Blank; M Lorber; L Stojanovich; J Rovensky; J Chapman; Y Shoenfeld
Journal:  Ann Rheum Dis       Date:  2005-03-18       Impact factor: 19.103

Review 4.  Current treatment of antiphospholipid syndrome: lights and shadows.

Authors:  Gerard Espinosa; Ricard Cervera
Journal:  Nat Rev Rheumatol       Date:  2015-06-30       Impact factor: 20.543

Review 5.  Pulmonary hypertension in antiphospholipid syndrome.

Authors:  Stéphane Zuily; Denis Wahl
Journal:  Curr Rheumatol Rep       Date:  2015-01       Impact factor: 4.592

Review 6.  Valvular heart disease in antiphospholipid syndrome.

Authors:  Stéphane Zuily; Olivier Huttin; Shirine Mohamed; Pierre-Yves Marie; Christine Selton-Suty; Denis Wahl
Journal:  Curr Rheumatol Rep       Date:  2013-04       Impact factor: 4.592

7.  Pulmonary hypertension imitating HELLP syndrome.

Authors:  Adam Morton
Journal:  Obstet Med       Date:  2013-07-25

Review 8.  The Heart and APS.

Authors:  Mary-Carmen Amigo
Journal:  Clin Rev Allergy Immunol       Date:  2007-04       Impact factor: 8.667

9.  D-dimer level and the risk for thrombosis in systemic lupus erythematosus.

Authors:  Haifeng Wu; Daniel J Birmingham; Brad Rovin; Kevin V Hackshaw; Nabil Haddad; Douglas Haden; Chack-Yung Yu; Lee A Hebert
Journal:  Clin J Am Soc Nephrol       Date:  2008-11       Impact factor: 8.237

10.  Complete resolution of a mitral valve vegetation with anticoagulation in seronegative antiphospholipid syndrome.

Authors:  Yuheng Ruan; Jonathan S Bridges; Kapil Kumar; Jonelle A Raphael; Subroto Acharjee; Francine K Welty
Journal:  Clin Rheumatol       Date:  2008-08-21       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.